Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Operating Income of $257.78 million for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $257.78M | +32.1% |
| 2024 | $195.12M | +124.8% |
| 2023 | $86.81M | -14.8% |
| 2022 | $101.84M | +94.4% |
| 2021 | $52.38M | +26.8% |
| 2020 | $41.30M | +29.8% |
| 2019 | $31.82M | +190.2% |
| 2018 | -$35.30M | -88.9% |
| 2017 | -$18.68M | +3.1% |
| 2016 | -$19.28M | +5.5% |
| 2015 | -$20.40M | -39.8% |
| 2014 | -$14.59M | -41.5% |
| 2013 | -$10.31M | -97.5% |
| 2012 | -$5.22M | +14.2% |
| 2011 | -$6.08M | -51.1% |
| 2010 | -$4.02M | +44.7% |
| 2009 | -$7.28M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $66.27M | +30.2% | -0.0% |
| June 30, 2025 | $66.30M | +22.2% | +4.6% |
| March 31, 2025 | $63.37M | +133.6% | +24.5% |
| September 30, 2024 | $50.91M | +236.9% | -6.2% |
| June 30, 2024 | $54.25M | +16.2% | +100.0% |
| March 31, 2024 | $27.13M | -23.8% | +172.9% |
| September 30, 2023 | -$37.19M | -248.1% | -179.6% |
| June 30, 2023 | $46.70M | +63.5% | +31.1% |
- CATALYST PHARMACEUTICALS, INC. showed an increase of +32.1% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, CATALYST PHARMACEUTICALS, INC.’s operating income has grown by 3643.1% (from -$7.28 million to $257.78 million).
- The most recent figure is from CATALYST PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: